SecBot SecBot
PRESS-RELEASE ·Filed Jun 2, 2026

VERA

Vera Therapeutics
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The accelerated eGFR analysis and sBLA timeline de-risks the path to full approval and increases the probability of an earlier commercial launch. Traders should watch for the PDUFA date on July 7, 2026, and the eGFR results in Q3 2026. Positive outcomes could drive substantial upside.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.26
T+0 close · Jun 2, 2026 · via day close
Latest settled
+17.79%
T+60 · $36.82
Vs SPY
+16.67%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $31.26entry
  2. T+1 · 6mo ago +0.03%α +0.75% · $31.27
  3. T+5 · 5mo ago +1.76%α +4.72% · $31.81
  4. T+20 · 5mo ago +36.47%α +38.03% · $42.66
  5. T+60 · 3mo ago +17.79%α +16.67% · $36.82

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vera Therapeutics announced FDA alignment on a revised, earlier eGFR analysis plan for atacicept in IgA Nephropathy, pulling the analysis forward to Q3 2026 (from 2027). This accelerates the potential path to full approval, with an sBLA submission planned for Q4 2026. The PDUFA date for accelerated approval remains July 7, 2026.

Key Facts

  • FDA aligned on revised ORIGIN 3 eGFR analysis plan, results now expected Q3 2026 (pulled forward from 2027).
  • Pending positive eGFR results, Vera plans to submit sBLA for full approval in Q4 2026.
  • PDUFA date for accelerated approval of atacicept in IgAN remains July 7, 2026.
  • Atacicept has Breakthrough Therapy Designation for IgAN.
  • ORIGIN Phase 2b and Phase 3 trials met primary endpoints with statistically significant proteinuria reduction and eGFR stabilization.

Financial Impact

Accelerated full approval timeline could bring atacicept to market earlier, potentially adding hundreds of millions in peak sales. Vera's market cap is $2.4B; a positive eGFR readout and subsequent full approval could significantly increase valuation.

revenuemarket cap

Risk Factors

  • FDA may not approve accelerated approval by July 7, 2026.
  • eGFR analysis in Q3 2026 could be negative, delaying or preventing full approval.
  • Competition from other IgAN therapies (e.g., Tarpeyo, Filspari) could limit market share.
  • Clinical trial risks in expanded indications (membranous nephropathy, FSGS).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304986

Track record

25 reports on VERA

Performance horizon

12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $28.10 +2.00% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $28.10 −6.43% settles Nov 17
  5. Nov 5, 202611d ago 8-K Bullish 6/10 No price data
  6. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $28.10 −5.66% ▼ −5.66% −8.25% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $28.10 −12.11% ▼ −4.66% −3.75% vs SPY
  8. Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $28.10 −3.27% ▲ +5.09% +4.39% vs SPY
  9. Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $28.10 −16.54% ▲ +0.98% +0.16% vs SPY
  10. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (11h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026